Showing results (11-20 of 39) with videos related to
Sort By:
Pageof 4
Biochemical Pharmacology|September 12, 1991
In vivo covalent binding of clofibric acid to human plasma proteins and rat liver proteinsB C Sallustio, K M Knights, B J Roberts, et al.Australian and New Zealand Journal of Medicine|October 1, 1981
Relationship of psychological factors to failure of antihypertensive drug treatmentR Zacest, C G Barrow, M W O'Halloran, et al.Therapeutic Drug Monitoring|July 1, 1991
Improved high-performance liquid chromatography assay for atenolol in plasma and urine using fluorescence detectionR G Morris, N C Saccoia, B C Sallustio, et al.Clinical Pharmacology and Therapeutics|September 1, 1987
Disposition of unchanged cisplatin in patients with ovarian cancerP A Reece, I Stafford, M Davy, et al.Cancer Chemotherapy and Pharmacology|January 1, 1985
Nonlinear renal clearance of ultrafilterable platinum in patients treated with cis-dichlorodiammineplatinum (II)P A Reece, I Stafford, J Russell, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 1, 1986
Reduced ability to clear ultrafilterable platinum with repeated courses of cisplatinP A Reece, I Stafford, J Russell, et al.British Journal of Clinical Pharmacology|August 1, 1985
Prednisolone protein binding in renal transplant patientsP A Reece, A P Disney, I Stafford, et al.Cancer Chemotherapy and Pharmacology|January 1, 1989
Influence of infusion time on unchanged cisplatin disposition in patients with ovarian cancerP A Reece, I Stafford, M Davy, et al.Clinical Pharmacology and Therapeutics|April 1, 1996
Inhibition of tacrine oral clearance by cimetidineS T Forgue, P A Reece, A J Sedman, et al.Cancer Chemotherapy and Pharmacology|January 1, 1987
A model for ultrafilterable plasma platinum disposition in patients treated with cisplatinP A Reece, I Stafford, J Russell, et al.Pageof 4